Investors File Securities Class Action Lawsuit Against Novelos Therapeutics, Inc. (NVLT) Over Statements Regarding Length of Phase 3 Clinical Trial Of Cancer Drug NOV-002
A securities class action lawsuit was filed against Novelos Therapeutics, Inc. (NVLT) in the United States District Court for the District of Massachusetts on behalf of purchasers of Novelos Therapeutics, Inc. (NVLT) stock during the period between December 14, 2009 and February 24, 2010 (the class period), for violations of the federal securities laws, according to a securities class action lawsuit filing news report.
The Novelos Therapeutics, Inc. (NVLT) securities class action lawsuit complaint reportedly alleges that defendants violated federal securities laws by, among other things, making false and misleading statements regarding the length of the Phase 3 clinical trial of the Novelos Therapeutics’s new drug candidate, NOV-002, which was being evaluated as a treatment for advanced non-small cell lung cancer when used in combination with first-line chemotherapy.
If You Have Thoughts On The Novelos Therapeutics, Inc. (NVLT) Securities Class Action Lawsuit, Share Your Class Action Comments Below.